Clinical Trial Update: Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports results from a Phase 1/2 study evaluating intravenous AP-SA02 for safety, tolerability, and efficacy in subjects with Staphyl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Staphylococcus Aureus Bacteremia

Drugs mentioned

• AP-SA02

Snippet

Sponsor: Armata Pharmaceuticals, Inc. | Conditions: Bacteremia, Staphylococcus Aureus | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-03-23